期刊文献+

三羟异黄酮对肝癌细胞HepG2的ADAM17表达的调节 被引量:2

Genistein's regulation to the gene ADAM17 expression on hepatocarcinoma cell line HepG2
下载PDF
导出
摘要 目的:观察三羟异黄酮(genistein)对肝癌细胞HepG2的生长增殖及ADAM17基因表达的影响。方法:培养肝癌细胞HepG2,加入三羟异黄酮特异性阻断酪氨酸蛋白激酶(TPK),MTT法观察genistein对HepG2细胞生长增殖的影响,PCR分析ADAM17基因水平变化,免疫组化法观察细胞水平ADAM17蛋白表达的变化。结果:经过genistein处理的肝癌细胞HepG2生长增殖受到明显抑制,在48、72和96小时有统计学意义(P<0.01);而且ADAM17的基因表达和蛋白表达都受到明显抑制(P<0.05),抑制程度呈现时间依赖性关系。结论:三羟异黄酮可以通过抑制TPK通路抑制肝癌细胞HepG2的生长增殖,并且抑制ADAM17基因和蛋白表达水平,从而间接调节HepG2细胞生长信号的传递。 Objective:To explore the effects on the proliferation and gene ADAM17 expression of hepatocareinoma cell line HepG2 after treated with genistein. Methods: Culture HepG2 cells in vitro and treat the cells with genistein to block tyrosine protein kinase (TPK), then assay the proliferation by MTT, analyse the expression on gene level by reverse transcription PCR and on protein level by cellular immunohistochemistry at 24, 48, 72 and 96 hours following treatment. Results: After the HepG2 cells were treated with genistein, proliferation was significantly inhibited compared to the control groups at 48,72 and 96 hours (P 〈0.01 ), and the expression difference of gene ADAM17 of the cells was statistically inhibited both in gene level and protein level (P 〈0. 05), and further, the inhibited degree showed time - dependent. Conclusion: Genistein can inhibit the proliferation of HepG2 ceils and lower the gene ADAM17 expression by inhibiting the TPK pathway, thereby indirectly regulate the growth signal transmission of hepatocarcinoma cells.
出处 《现代肿瘤医学》 CAS 2009年第9期1640-1643,共4页 Journal of Modern Oncology
关键词 三羟异黄酮 HEPG2 ADAM17 MTT PCR技术 免疫组化 genistein HepG2 ADAM17 MTT PCR immunohistochemistry
  • 相关文献

参考文献13

  • 1钦伦秀,孙惠川,汤钊猷.原发性肝癌研究进展——2006沪港国际肝病大会纪要[J].中华外科杂志,2006,44(15):1070-1074. 被引量:56
  • 2杨玲,李连弟,陈育德,D.M.Parkin.中国2000年及2005年恶性肿瘤发病死亡的估计与预测[J].中国卫生统计,2005,22(4):218-221. 被引量:336
  • 3Carr BI. Hepatocellular carcinoma: current management and future trends[ J]. Gastroenterology, 2004,127 : $218 - $224.
  • 4Borrell - Pages M, Rojo F, Albanell J, et al. TACE is required for the activation of the EGFR by TGF -alpha in tumors[ J]. EMBO J, 2003,22:1114 - 1124.
  • 5Smith N J, Luttrell LM. Signal switching, crosstalk, and arrestin scaffolds - Novel G protein - coupled receptor signaling in cardiovascular disease[J]. Hypertention, 2006, 48 (2): 173-179.
  • 6Davis GE, Senger DR. Endothelial extracellular matrix - biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization [ J ]. Cireulati Res, 2005,97 ( 11 ) : 1093 - 1107.
  • 7何伍,凌霄.小分子EGFR酪氨酸激酶抑制剂研究进展[J].中国药学杂志,2007,42(22):1685-1688. 被引量:16
  • 8Berasain C, Castillo J, Prieto J, et al. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system [ J ]. Liver International, 2007, 27 (2) : 174 - 185.
  • 9McGowan PM, McKieman E, Bolster F, et al. ADAM - 17 predicts adverse outcome in patients with breast cancer[ J]. Ann Oncol, 2008, 19 (6) : 1075 - 1081.
  • 10Franovic A, Robert I, Smith K, et al. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17 [J]. Cancer Res, 2006,66 (16) : 8083 -8090.

二级参考文献52

  • 1李连弟,鲁凤珠.1990—1992年中国恶性肿瘤死亡流行分布情况分析[J].中华肿瘤杂志,1996,18(6):403-407. 被引量:226
  • 2李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 3Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0. IARC Cancer Base No 5. Lyon, IARCPress, 2004.
  • 4Yang L, Parkin DM, Li LD, et al. A comparison of the sources ofeancer mortality in China. Cancer Causes Conhol, 2004, 15(7) : 1581-7.
  • 5International Agency for Research on Cancer. Cancer Mortality Database. http://www-deodb, iarc. fr/who/menu, hun.
  • 6Parkin DM, Whelan SL, Ferlay J, et al. Cancer in Five Continents Vol.VIII. IARC Scientific Publication No. 155, Lyon, FraQce: IARC-Press; 2002.
  • 7United Nations, Population Division (2003) World Population Prospects: The 2002 Revision. Population Database. http://esa, un.org/unpp.
  • 8Yang L, Parkin DM, Li LD, et al. Time Trends in Cancer mortality in China: 1987-1999. International J Cancer, 2003,106(5) :771-83).
  • 9Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer mortality in China: 1991 - 2005. British Journal of Cancer, 2004, 90:2157-2166.
  • 10Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer in cidenee in China for 2000 and projection for 2005. Cancer Epidemiology, Biomarkers & Prevention. 2005, 14( 1 ) : 243-250.

共引文献405

同被引文献46

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部